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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Tocopherol from raw pumpkin seeds has been reported to be effective in
the alleviation of diabetes through its antioxidant activities. This study evaluates the antidia-
betic activities of the tocopherol fraction of raw seeds of Cucurbita pepo L. (CPSE) in a dia-
betic rat model. In addition, the putative action mechanisms of its botanicals were
computationally investigated.
Methods: Seed water activity (Aw) was assessed. Tocopherol was extracted and quantified
from raw seed oil. The effect of CPSE was studied in poloxamer-407 (PX-407)-induced type 2
diabetic Wistar rats. Glycemic, insulinemic, and lipid profiles, as well as lipid peroxidation sta-
tus, were evaluated. Glucagon like peptide-1 (GLP-1) content in the cecum was evaluated andof Biochemistry, Patna University, Patna, Bihar, India.
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In vivo and in silico validation of Cucurbita pepo tocopherol 677histopathological analysis of the pancreas was performed. Further, HYBRID and FRED docking
were performed for 10 documented CPSE botanicals, for putative action mechanisms concern-
ing three proteins [protein-tyrosine phosphatase 1B (PTP-1B), peroxisome proliferator-
activated receptor gamma (PPAR-g), and dipeptidyl peptidase IV (DPP-IV)] known to have dia-
betic therapeutic potential.
Results: The Aw of raw seeds was found to be 0.544  0.002. Using tocopherol standards, HPLC
determination of CPSE revealed the presence of tocopherol isomers (a, b, g, and d). The
tocopherol content was found to be 107.4  2.9 mg/100 g of CPSE. When compared to diabetic
control (DC) rats, the CPSE-treated diabetic rats presented a significant amelioration of glyce-
mia, insulinemia, and lipid dysmetabolism. A remarkable reduction in oxidative markers and
improved cecal and pancreatic characteristics were also observed. Tocopherol isomers have
shown a considerable interaction potential with the aforesaid proteins in docking.
Conclusion: The results provide pharmacological evidence of CPSE as an antihyperglycemic
mediated by the interaction of various botanicals with multiple targets operating in diabetes
mellitus (DM).
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic dis-
order characterized by abnormalities of glucose homeostasis
by various organs. It accounts for about 85e95% of all diag-
nosed cases of diabetes and is associated with considerable
morbidity and mortality. Several treatment strategies are
being adopted to ameliorate T2DM by therapeutic inter-
vention.1e3 Synthetic drugs, despite having excellent po-
tencies, had offered unwanted therapeutic profiles marked
by fluid retention, drug-induced hypoglycemia, liver mal-
functioning, weight gain, and cardiac dysfunction.4
Extensive research has been carried out worldwide on
rational drug design,5 to identify and optimize new leads
for molecular targets of T2DM, such as nuclear receptor
peroxisome proliferator-activated receptor gamma (PPAR-
g),6,7 human incretin-degrading enzyme dipeptidyl pepti-
dase IV (DPP-IV),5,8 and protein-tyrosine phosphatase 1B
(PTP1 B).5,9 The PPAR-g regulates glucose metabolism and
fatty acid storage by enhancing the insulin action.5e7 The
DPP-IV is a membrane-bound, serine protease ectoenzyme
responsible for the degradation and inactivation of a
number of glucose regulating incretin hormones, like
glucagon like peptide-1 (GLP-1). GLP-1 causes an increase
in the amount of insulin released from pancreatic b-
cells.5e8 Thus, diabetic conditions can be reduced either by
injecting an excess of GLP-1 or its analogues, inhibiting the
action of DPP-IV.10 PTP-1B inhibitors have emerged as a
promising potential therapeutic target for T2DM, as they
are negative regulators of the insulin signaling pathway and
regulate lipogenesis and hypertriglyceridemia.5,9
These therapeutic targets may improve the efficacy-to-
safety ratio, resulting in durable maintenance of glycemic
control in the majority of people with diabetes. Numerous
structurally unrelatednatural products, includingalkaloids and
flavonoids, have been described to interact with these target
proteins in micromolar concentrations.5,11 Therefore, there is
much scope for herbal medicines, which have emerged as a
safe and relatively economical therapy found to beeffective as
add on therapy, in the long-term management of T2DM.11
Pumpkin [Cucurbita pepo (C. pepo)] seed oil (about
11e31% of total seed content) has been implicated as anutraceutical due to its macro- and micro-constituent
composition. The seed oil is a rich source of proteins,
diverse fatty acids, and antioxidant vitamins, such as
carotenoids and tocopherols.12e14 It has been documented
that the tocopherol content of the oil ranged from 27 mg/
g to 75 mg/g of oil for a-tocopherol, from 75 mg/g to
493 mg/g for g-tocopherol, and from 35 mg/g to 1110 mg/g
for d-tocopherol.14,15 So far, several pharmacological
properties of pumpkin have been reported including
lipid-lowering,16,17 hepatoprotective,17 anticarcinogenic,18
antimicrobial,19 and treatment of urination disorders,20 in
addition to antidiabetic and antioxidant activities.20e25
Despite of the folkloric use of seed extract of C. pepo,
there is insufficient supporting scientific data forming the
basis of the present investigation. It systematically evalu-
ates the beneficial effects of the tocopherol fraction of
pumpkin seed oil in vivo in poloxamer-407 (PX-407)-induced
diabetic Wistar rats. Intraperitoneal administration of the
nonionic copolymer PX-407 in rats induces hyperglycemia
with impaired response and loss of b-cell sensitivity to
glucose, which is considered as a useful diabetic model to
study the activity of antihyperglycemic agents.26 In addi-
tion, in silico molecular docking was performed using
HYBRID27 and FRED28 programs, to propose the interaction
potential of 10 botanicals from C. pepo seeds, documented
hitherto concerning three proteins (PTP-1B, PPAR-g, and
DPP-IV) known to have diabetic therapeutic potential.Methods
Chemicals
PX-407, heparin, glucose oxidase, peroxidase, o-dia-
nisidine, bovine serum albumin, Coomassie brilliant blue G-
250, cysteine hydrochloride, thiosemicarbazide, and
diacetyl monoxime were purchased from Sigma Chemical
Co. (St Louis, MO, USA). Tocopherol isomers were pur-
chased as follows: a-tocopherol e Fluka (Sigma-Aldrich, St.
Louis, MO, USA), b-tocopherol e Matreya, LLC (Matreya
LLC, 168 Tressler St, Pleasant Gap, PA 16823, United
States), g-tocopherol and d-tocopherol e Supelco (Sigma-
678 S.K. Bharti et al.Aldrich, St. Louis, MO, USA). The blood glucose diagnostic
kit was purchased from Span Diagnostic Limited, Surat,
India and the glycosylated hemoglobin (HbA1c) diagnostic
kit was from Monozyme India Limited, Secunderabad, India.
The biochemical kits for measuring the lipid profiles were
procured from Biosys, Bangalore, India and ketamine was
from Neo Pharmaceuticals, Bangalore, India. The enzyme-
linked immunosorbent assay (ELISA) kit for insulin assay
and GLP 1 determination was purchased from Millipore
Corporation (Linco Research, Inc., St. Charles, MO, USA,
63304). Casein (refined grade) was procured from Nimesh
Corporation (Mumbai, India). The salt mixture was procured
from SISCO Research Laboratories Pvt. Ltd. (Mumbai,
India). The standard pellet diet (SPD) was purchased from
Lipton Rat Feed Ltd. (Pune, India). All other chemicals and
solvents used in this study were obtained from Merck, India
and were of analytical grade.
Collection and preparation of plant materials
The seeds of C. pepo L. were collected from Hajipur in
northern India, in 2009. It was hermetically sealed in plastic
packaging, and purchased from a local folk medicinal plant
dealer in Patna, Bihar, India. The plant was identified and
botanically authenticated at source and a voucher spec-
imen (CAS#106/2011) was deposited in the postgraduate
department of biochemistry, Patna University, Patna for
future reference. No fungal development was assured by
determining the water activity (Aw) with an Aqualab Aw
meter (model CX-2; Decagon Devices, Inc., Hopkins Court
Pullman, WA 99163- USA).30 The plastic cap of the Aqualab
was filled with ground seeds and the analysis was per-
formed in two replicates at 24  1C. Below a threshold of
AwZ 0.62, there is usually no notable fungal development,
which is a good indicator of the preservation potential of
the product and its microbiological stability with time.
Tocopherol extraction from pumpkin seeds
The procedure used was the one described by Murkovic
et al (2004).31 Briefly, ground pumpkin seeds were added
with anhydrous sodium sulfate (1:5 ratio) to remove the
water and subsequently tocopherol was extracted with n-
hexane in an ultrasonic bath for 30 minutes. To prevent
oxidation, 80 mg of butylated hydroxytoluene were added.
At the end of the extraction, the extract was filtered and its
volume was reduced on a rotary evaporator, brought to
1000 mL with n-hexane, and was named CPSE.
Analysis and quantification of tocopherol in CPSE by
HPLC
Tocopherol quantification was carried out for four external
tocopherol standards and CPSE by the standard method of
ISO 9936 (2006).32 The standard solutions were prepared
and preserved in HPLC grade hexane in flasks without
actinic activity. High-performance liquid chromatography
(HPLC) was performed on an Agilent 1100 Series HPLC sys-
tem equipped with a BinPump G1312 A binary pump, a
thermostatted ALS G1329 A auto sampler, an ALSTherm
G1330 B auto sampler thermostat, a COLCOM G1316 Athermostatted column compartment, an FLD G1321 A
fluorescence detector (Agilent Technologies, Hewlett-
Packard-Strasse 8, Waldbronn, Germany) operating at an
excitation wavelength of 290 nm and an emission wave-
length of 330 nm. The analytical column used was a Phe-
nomenex (Torrance, CA, USA) Luna (250  4.60 mm),
packed with 5 mm silica, S/N 00G-4274-E0. The mobile
phase used was heptane-THF (1000 þ 40 v/v) at a constant
flow rate of 1.0 mL/minute. The injection volume was in
the range of 5e100 mL in order for all the tocopherol iso-
mers to elute in the calibration range. The retention times
of a-tocopherol and g-tocopherol were in the range of
11.0e11.5 minutes and 18.0e19.0 minutes, respectively.
The elution order was as follows: a-tocopherol, b-tocoph-
erol, g-tocopherol, and d-tocopherol. These tests were
repeated four times to obtain the most representative
possible equations calculated by linear correlation coeffi-
cient (R2). This was found to be greater than 0.9998 for all
tocopherol isomers (Table S1). The detection of tocoph-
erols was done using a fluorometer, which made it possible
to inject and proportion the oil directly in hexane. Excita-
tion was set at 290 nm, thus inducing fluorescence emission
by tocopherols at 330 nm.
Experimental animals and induction of diabetes
The healthy male albino Wistar rats (150e160 g) were kept
under good hygienic conditions and fed on SPD and ad
libitum water throughout the experimental period. Rats
had undergone multiple administrations of freshly prepared
PX-407 solution (10 mg/kg body weight once a day for
6 weeks) followed by 1 hour of fasting. They were allowed
to access the food and water ad libitum for 6 weeks. Rats
with fasting blood glucose level of 200 mg/dL or higher
were considered to be diabetic and were used in the study.
During the experimental period, the animals were observed
within cages daily for mortality, or signs of toxic effects
(see also supplemental text). The experimental study was
approved by the Institutional Animal Ethics Committee of
Department of Health, Patna, Bihar, India.
Experimental design
The rats were divided into four different groups having six
animals each. These were the DC group (diabetic control
rats), NC group (nondiabetic control rats), DT2 group (dia-
betic rats treated with 2 g of CPSE/kg body weight), and
DT5 group (diabetic rats treated with 5 g of CPSE/kg body
weight). Body weights were recorded weekly during the
experimental period. Treatment with CPSE was started
from the 3rd week of PX-407 injection, which was consid-
ered as the 1st day of treatment.
Analytical parameters
Glycemic, insulinemic, and lipidic profile
Blood samples were collected from the caudal vein
by means of a small incision at the end of the tail. Plasma
glucose levels were measured using a glucose oxidase
commercial kit (Span Diagnostic Limited). Taking into
account the variability of serum glucose levels in rats,
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(Monozyme India Limited, Secunderabad, India). Serum
insulin (SI) was estimated by a radioimmunoassay method
using the kit from Bhabha Atomic Research Centre, Mum-
bai, India. Insulin sensitivity of individual animals was
evaluated using the previously validated homeostasis
model assessment (HOMA) index33 using the formula:
HOMA RZFI ðmU=mlÞFBG ðmg=dlÞ405 . The values used (insulin and
glucose) were obtained after overnight food deprivation.
The serum was separated and analyzed spectrophotomet-
rically for triglyceride (TG) and total cholesterol (TC) using
a diagnostic reagent kit (Nicholas Piramal India Ltd.,
Mumbai, India).
Endogenous enzymatic and nonenzymatic
antioxidant levels
At the end of the experimental period, rats were fasted
overnight and sacrificed under anesthesia (i.p. ketamine,
150 mg/kg body weight). The whole liver was dissected out
subsequent to saline water perfusion, followed by prepa-
ration of the 10% liver homogenate with ice-cold saline-
EDTA. The protein content was measured with the Folin
phenol reagent.34 The homogenate was further subjected
to the evaluation of nonenzymatic [reduced glutathione
(GSH) and total thiols] and enzymatic antioxidant [cata-
lase, glutathione-S-transferase (GST), and superoxide dis-
mutase (SOD)] status using spectrophotometric methods.35
Lipid peroxidation levels of the liver homogenates were
also determined.36
GLP-1 content in the cecum
The cecal contents from the excised cecum of sacrificed
rats were removed. The cecal tissue was thoroughly washed
with cold phosphate buffer saline (PBS; pH 7.4) and ho-
mogenized at 4C in PBS containing DPP-IV inhibitor (20 mL/
mL PBS). The homogenate was then centrifuged at
10,000  g for 10 minutes, followed by the supernatant
collection and GLP-1 level determination by ELISA kit,
(Millipore Corporation, Linco Research, Inc., St. Charles,
MO, USA).
Histological studies
The pancreas of animals from different experimental
groups were examined in situ, excised, and perfused with
10% neutral formalin. They were then embedded in
paraffin, thinly sectioned using a microtome, stained with
hematoxylin-eosin (HE), mounted in neutral DPX medium,
and examined under a light microscope. Histopathological
studies were performed to estimate the beta cell mass,
increase in the islet number, and to check the quality of
insulitis.
Molecular docking studies
 Data collection and ligand preparation
To gain further insight in to the interaction of fruit extracts
with diabetic proteins, 10 active botanicals of CPSE,reported in various studies in the literature12,14,20,21 were
selected for docking studies. Two-dimensional structures of
these botanicals were either retrieved from PubChem29,37
or drawn using the MSketch tool (v-5.8.0) available from
ChemAxon (Graphisoft Park, Budapest, Hungary).38 The
correct protonation states were enumerated by the
tautomer enumeration program.39 The partial charges were
assigned by MMFF9440 force-field available in the mol-
charge39 program. Further, stereocenters were enumerated
using flipper39 in those molecules where a stereocenter
does not have a specified stereochemistry. The physico-
chemical properties, as well as the 3D similarity of 10 bo-
tanicals and a native ligand used in this study were
calculated by MolProp41 and OEChem shape toolkits.42 The
3D conformers were generated using OMEGA39 and used for
docking to three diabetic proteins, namely DPP-IV, PPAR-g,
and PTP1 B. The numbers of conformers were determined
by counting the rotatable bonds present in the individual
ligand.
 Protein preparation and self-docking
The receptors for three selected proteins, namely DPP-
IV, PPAR-g, and PTP1 B, were prepared using the FRED-
receptor preparation tool.39 There are 72, 113, and 120
structures available in the PDB database37 for DPP-IV, PPAR-
g, and PTP1 B, respectively. Of these, PDB IDs 4AS5 (1.62 A˚
resolution),43 2HWQ (1.97 A˚ resolution),44 and 2F71 (1.55 A˚
resolution)45 were selected, respectively, for DPP-IV, PPAR-
g, and PTP1 B. The active site was identified on the basis of
bound ligand to the receptors. The volume of active sites
(outer contour) of DPP-IV, PPAR-g, and PTP1 B are 2057,
2016, and 1623 cubic angstroms, respectively. Protein
constraints were set on critical residues, the interaction of
which is necessary for ligand binding of the aforesaid pro-
teins. These hydrogen bonding constraints are set on resi-
dues E205, E206, Y631, Y547 in DPP-IV,43 H449, Y473 in
PPAR-g,46,47 and D181, S216, A217, R221 in PTP1 B48,49
active sites. The protein-based docking constraints are in-
teractions between ligands and a heavy atom of the
protein-amino acid residues. This does not affect how a
given pose scored, but affects the process of selection of
poses to score. The botanicals satisfying at least one per set
of constraint are successfully docked in order to minimize
the rate of false-positive detection. Any pose that does not
match the docking constraints is rejected and replaced by
the next best scoring pose. The correctness of the protein
preparation step was checked by a self-docking process, in
which the co-crystallized ligand was re-docked in the re-
ceptor. For acceptable self-docking, the root mean square
deviation (RMSD) was kept <2.00 A˚ compared to the
reference structure.50 The HYBRID27 and FRED28 docking
program was used to dock multi-conformer molecules into a
receptor using a two-step process: (1) Systematic exhaus-
tive search: This performs systematic exhaustive search by
enumerating every possible rotation and translation of each
conformer of the ligand being docked within a box enclos-
ing the active site. Poses are discarded based on either
clash with the protein or extending too far from the binding
site (using the receptor’s negative image outer contour).
Further, two optional poses rejection steps were employed:
(a) based on the receptor’s negative image inner contour
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have at least one heavy atom falling within the inner con-
tour are discarded. A pose that does not match the docking
constraints will be rejected and replaced by the next best
scoring pose. In the case of FRED, the selected poses are
then scored using the Chemgauss3 scoring function. HYBRID
additionally considers a similarity of the ligand to the re-
ceptor bound ligands. The similarity is calculated based on
the match of the 3D shape and chemical features of the
docking ligand and bound ligand. It is evident from Table 6
that some of the ligands have low 2D Tanimoto51 co-
efficients, calculated based on Extended-Connectivity Fin-
gerprints (ECFP4) keys based on molecular fingerprints52
than 3D Tanimoto coefficients. The selected poses are
scored using the scoring function. All the selected poses are
sorted by score and the top scoring poses are passed to the
optimization step. (2) Optimization and final scoring: The
top scoring poses obtained after exhaustive searching are
optimized and scored by enumerating the nearby positions
of each pose having the initial pose. One positive and one
negative step for each translational and rotational degree
of freedom are taken. The poses are finally scored with
Chemgauss4 and the Chemical Gaussian Overlay (CGO)
scoring function in FRED and HYBRID, respectively. Ten
botanicals from C. pepo were docked to three proteins,
namely 2F71 (PTPB1), 2HWQ (PPAR-g), and 4A5 S (DPP-IV)
and molecular interactions were plotted using PoseView.53Statistical analysis
Data were expressed as the mean  S.E.M. For statistical
analysis of the data, the group means were compared by
one-way ANOVA with post hoc analysis. The Tukey-KarmerFigure 1 HPLC analysis of (A) standard tocopherols and (B) tocpost hoc test was applied to identify the significance
among groups. Graphs were plotted using MATLAB version
7.8.0 R2009a, Natick, MA, USA: The Mathworks Inc. 2009. A
p value of 0.001 was considered to be statistically
significant.
Results
Characterization of CPSE
The Aw of raw seeds was found to be 0.544  0.002. This
showed that the seeds were stable with respect to the
potential growth of microorganisms.30
Tocopherol analysis of CPSE by HPLC
The HPLC analysis of tocopherol standards is shown in
Fig. 1A and that of the CPSE with respect to a standard one,
in Fig. 1B. The seeds had a tocopherol content of
107.4  2.9 mg/100 g of CPSE.14
Effect of CPSE on body weight and lipid profile
The DC rats demonstrated a higher body weight (þ107%;
p < 0.001) when compared with the NC rats (Table 1). No
significant changes in body weight gain were encountered
between the treated groups of diabetic rats (DT2 and DT5)
versus the DC rats (Table 1). The DC rats also presented
higher TC (þ173%; p < 0.001) and TGs (þ589%; p < 0.001)
values compared to NC rats. These changes in biochemical
indices are expected as the diabetic condition progresses.
The treated diabetic rats (DT2 group) showed significantlyopherols from CPSE with their main peaks. T Z tocopherol.
Table 1 Effects of CPSE on body weight, glucose, HbA1c, insulin, HOMA-IR, TC, and TGs on different rat groups.
Control rats Treated rats
NC DC Effect DT2 Effect DT5 Effect
Body weight (g) 157.13  2.30 325.50  2.73** \ 342.00  3.23 5 329.42  2.34 5
Glucose (mg/dL) 133.72  2.08 614.85  3.84** \ 569.43  17.66* Z 398.93  5.53* Z
HbA1c (%) 3.38  0.12 12.59  0.12** \ 11.39  0.25 Z 12.46  0.07 5
Insulin (pmol/L) 50.31  0.99 184.85  1.28** \ 174.98  0.36* Z 154.62  1.21* Z
HOMA-IR 2.34  0.98 40.35  2.02** \ 32.13  1.33* Z 24.31  1.06* ZZ
TC (mg/dL) 75.95  1.17 208.87  1.37** \ 178.79  2.32* Z 206.68  0.95 5
TGs (mg/dL) 60.25  0.71 418.06  3.19** \ 357.65  0.98* Z 413.98  1.23 5
Results are mean  SEM of six rats per group.
* Statistically significantly different versus the normal control rat group (p < 0.001).
** Statistically significantly different versus the diabetic control rat group (p < 0.001).
Figure 2 Effect of treatment with CPSE on nonenzymatic antioxidants (A) glutathione (GSH) and (B) total thiols as well as (C)
thiobarbituric acid reactive substances (TBARS) and enzymatic antioxidants (D) glutathione-S-transferase (GST), (E) catalase and
(F) superoxide dismutase (SOD) in the liver homogenates of different rat groups. Each bar represents the mean  SE (n Z 6).
DCZ diabetic control animals; DT2Z diabetic animals treated with a low CPSE dose (2 g/kg body weight); DT5Z diabetic animals
treated with a high CPSE dose (5 g/kg body weight); NCZ untreated normal control animals. *p < 0.001, compared to the diabetic
control rats. **p < 0.001, compared to the normal control rats.
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Figure 3 Effect of CPSE treatment on (A) pancreas weight and (B) glucagon like peptide-1 (GLP-1) contents. Each bar represents
the mean  SE (nZ 6). DCZ diabetic control animals; DT2Z diabetic animals treated with a low CPSE dose (2 g/kg body weight);
DT5Z diabetic animals treated with a high CPSE dose (5 g/kg body weight); NC Z untreated normal control animals. *p < 0.001,
compared to the diabetic control rats. **p < 0.001, compared to the normal control rats.
Figure 4 Histopathology of pancreas showing variation in islet number, size, and grade of insulitis in each rat group. (A)
NC Z untreated normal control animals; (B) DC Z diabetic control animals; (C) DT2 Z diabetic animals treated with a low CPSE
dose (2 g/kg body weight); (D) DT5 Z diabetic animals treated with a high CPSE dose (5 g/kg body weight).
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(þ30.9%; p < 0.001), when compared with the DC coun-
terparts. The DT5 treatment had no lowering effects on TC
or on TGs levels (Table 1).
Effect of CPSE on glycemia, HbA1c, insulinemia,
and insulin resistance
As expected, the DC rats showed significantly (p < 0.001)
higher values of glucose (þ370%), HbA1c (þ280%), and in-
sulin (þ275%), together with higher insulin resistance
(HOMA-IR), when compared with their treated counterparts
(Table 1). Diabetic rats of both groups (DT2 and DT5)
showed a reduction in glucose levels, when compared to
the DC ones; nevertheless, the reduction was particularly
evident in the DT5 rats (-57.5%; p < 0.001). When
comparing the glucose levels of the DT5 versus the DT2
group rats, a significantly lower value in the first was found
(55.0%; p < 0.001) (Table 1). The 12-week treatment
program also significantly diminished the HbA1c levels
(8.3%; p < 0.01) in the diabetic rats, although no changes
were detected in the HbA1c levels of the DT5 group rats.
The CPSE treatments were able to significantly reduce
(p < 0.001) insulin levels in diabetic rats (Table 1). In
agreement with the abovementioned results, CPSE treat-
ments in diabetic rats (DT2 and DT5) significantly reduced
(p < 0.001) the insulin levels as well as insulin resistance,
evaluated by HOMA-IR index (Table 1). Nevertheless, this
drop in insulin resistance was more evident in the DT5 rats
(60.6%) than in the DT2 rats (26.8%).
Effect of CPSE on endogenous enzymatic and
nonenzymatic antioxidant levels
Reduced GSH
NC rats showed basal GSH levels of about 10.86  0.065
nmoles/mg of protein. PX-407 induction for 6 weeks led to
significant reduction (p < 0.001) in GSH levels (3.18  0.271Figure 5 Self-docking results compared with interactions prese
crystallized ligand. (A) UN7 docked to 2F71; (B) N7 F docked to 4Anmoles/mg of protein). Treatment with higher doses of
CPSE to diabetic rats (DT2 and DT5) produced a significant
(p < 0.001) improvement in GSH levels (Fig. 2A).
Total thiols
Basal total thiol levels in NC rats were found to be
8.78  0.96 mmoles/mg of protein. Diabetic rats showed
significantly decreased (p < 0.001) levels of total thiols
(3.16  0. 476 mmoles/mg of protein). Moreover, treatment
of diabetic rats with CPSE (DT2 and DT5) showed signifi-
cantly (p < 0.01) increased levels (Fig. 2B).
Lipid peroxidation
NC rats showed basal thiobarbituric acid reactive substances
(TBARS) levels of about 11.83 1.79 nmoles/g of liver tissue.
Diabetic rats showed significantly increased (p < 0.001)
TBARS levels (103.18 3.245 nmoles/g of tissue). Treatment
with CPSE (DT2 and DT5) significantly (p < 0.001) abolished
the increase in TBARS levels induced by PX-407 (Fig. 2C).
GST
Normal basal GST activity in NC rats was found to be
0.058  0.0009 U/mg of protein. Diabetic rats exhibited
significantly reduced (p < 0.001) levels of GST
(0.0062  0.0004 U/mg of protein). The two tested doses
(DT2 and DT5) of CPSE significantly (p < 0.001) increased
the levels of GST (Fig. 2D).
Catalase
Normal basal level of catalase activity in NC rats was found to
be 171.83  6.779 U/mg of protein. Diabetic rats showed
significantly decreased (p< 0.001) levels of catalase by about
more than threefold (i.e., 49.15 3.265).However, treatment
with CPSE (DT2 and DT5) showed significantly (p < 0.001)
increased levels of catalase to thenear normal values (Fig. 2E).
SOD
NC rats showed basal SOD levels of about 30.83  2.273 U/
mg of protein. Diabetic rats exhibited significantly reducednt in PDB (3D). Green docked compounds and yellowish co-
5 S; (C) DRY docked to 2HWQ.
Table 2 Botanicals documented for docking from seeds of
the C. pepo plant.
Compound no. Name Pub-chem CID
1 g-Tocopherol 92729
2 a-Tocopherol 14985
3 d-Tocopherol 92094
4 b-Tocopherol 6857447
5 b-Carotene 5280489
6 Lutein 448437
7 Cucurbitine 442634
8 b-Sitosterol 222284
9 Campesterol 173183
10 Squalene 638072
684 S.K. Bharti et al.(p < 0.001) levels of SOD by about one fourth (7.18  0.766
U/mg of protein). Treatment with CPSE (DT2 and DT5)
showed significantly (p < 0.001) increased levels of SOD to
the near normal values (Fig. 2F).
Effect of CPSE on pancreas weight
The pancreatic weight of diabetic rats was found to be
lower than those of the NC rats (p < 0.001). However, CPSE-
treated diabetic rats (DT2 and DT5) had enlarged pan-
creases compared with DC rats (NC: 2.46  0.08 g, DC:
1.32  0.04 g, DT2: 1.69  0.21 g, DT5: 1.91  0.19 g).
However, when the biochemical parameters were normal-
ized with respect to body weight, the CPSE-treated diabetic
rats showed an increase in pancreatic weight compared to
NC rats (Fig. 3A).
Effect of CPSE treatment on GLP-1 levels in cecum
tissue
To investigate whether CPSE treatment affected GLP-1
production, the incretin level was measured in intestinal
tissue. In the cecum, the diabetes (DC group) showed a
significant decrease (p < 0.001) in GLP-1 concentration,
which was 70% of NC rats. The CPSE treatment significantlyTable 3 Protein structures studied.
PDB ID Name Ligand ID RMSD (A˚) Inter
in PD
4A5 S Dipeptidyl peptidase IV
(DPP-IV)
N7 F 0.85 Tyr54
Tyr66
Glu2
Ser63
Gly6
2HWQ Peroxisome proliferator-
activated receptor
gamma (PPAR-g)
DRY 1.45 His44
2F71 Protein tyrosine
phosphatase 1B (PTP1 B)
UN7 0.97 Phe1
Arg2
Gly2
Ser21
Ile21
Phe1increased GLP-1 concentration. Due to the important
cecal tissue enlargement in these rats, GLP-1 content
expressed in picomoles per total cecum was 1.4-fold
higher in DT2 and 1.6-fold higher in DT5 than in DC rats
(Fig. 3B).
Histopathological analysis
The effect of CPSE on the number of pancreatic islets, its
size and the grade of insulitis on different rat groups can be
found in the online supplementary material. In the DC
group, the number and size of islets decreases significantly
(p < 0.001) and the grade of insulitis is also very high, when
compared to NC rats. In DC2 and DC5 rats there was a sig-
nificant improvement in the number of islets, as well as the
grade of insulitis (Fig. 4; Table S2).
LD50
The behavior of the treated rats appeared normal. No toxic
effect was reported up to the effective dose of the CPSE, as
there was no death in any of these groups.
Molecular docking studies
 Self-docking
In the case of PTP1 B and DPP-IV, the self-docking RMSD
was observed within 1 A˚, while for PPAR-g it was within
1.45 A˚, indicating acceptable quality of docking prepara-
tion. The 3D overlay of the co-crystal bound and docked
ligands is shown in Fig. 5 and the protein structures studied
along with interacting residues and type of interaction is
given in Table 3.
 CPSE botanicals docked to PTP1 B, PPAR-g, and DPP-IV
a. Docking with constraints
None of the 10 active CPSE compounds (Table 2) were
capable of docking to PTP1 B, while the number of botan-
icals docked to PPAR-g and DPP-IV were six and five,acting residues
B
Interacting residues in
self-docking
Major interactions
7 A; Tyr662 A Tyr547 A PiePi
2 A; Tyr631 A;
06 A; Glu205 A
Tyr666 A; Tyr631 A;
Lys554 A; Glu206 A;
Glu205 A
Hydrogen bond
0 A; Trp629 A;
28 A; Tyr547 A
Ser630 A; Trp629 A;
Trp627 A
Hydrophobic
9 A; Tyr473 A Tyr473 A; Ser342 A Hydrogen bond
82 A; Tyr46 A Phe182 A; Tyr46 A PiePi
54 A; Arg221 A;
20 A; Ala217 A;
6 A
Arg254 A; Arg221 A
Ala217 A;
Cys215AAsp181 A
Hydrogen bond
9 A; Ala217 A;
82 A
Ile219 A Hydrophobic
Table 4 Interaction of botanicals docked to PPAR-g and DPP-IV.
Compound no. Pub chem CID Hybrid score FRED score Interacting residues Major interactions
Botanicals docked to DPP-IV; bioactive ligand has FRED score (L10.24) and hybrid score (L10.24)
3 92094 7.056698 7.056698 E205, Y662 Hydrogen bond
S630, Y547, W629 Hydrophobic
1 92729 6.769999 6.709151 E205, Y662 Hydrogen bond
S630, Y547, W629 Hydrophobic
2 14985 6.014852 6.014852 Y662, Y666, Y631 Hydrogen bond
S630, Y547, W629 Hydrophobic
Y666 PiePi
4 6857447 5.745492 5.543730 E205, E206, Y662
Y547, W627, W629
Hydrogen bond
Hydrophobic
7 442634 3.490675 3.758782 Y662, H740 Hydrogen bond
Botanicals docked to PPAR-g; bioactive ligand has FRED score (e18.90) and hybrid score (e18.02)
3 92094 12.337214 12.901058 H449, C285 Hydrogen bond
C285, I341 Hydrophobic
1 92729 11.677748 12.260074 H449 Hydrogen bond
G284, I281, C285, Y327, L330, I341 Hydrophobic
4 6857447 11.559639 11.897834 H449 Hydrogen bond
I281, C285, Y327, L330, I341 Hydrophobic
2 14985 11.270902 12.379365 H449 Hydrogen bond
I281, C285, Y327, L330, M361, I341 Hydrophobic
9 173183 6.870636 6.424315 Y473 Hydrogen bond
I341, I330, C285, R288 Hydrophobic
8 222284 6.145874 5.925000 H449, Y473 Hydrogen bond
L333, L330, H449, C285, R288 Hydrophobic
In vivo and in silico validation of Cucurbita pepo tocopherol 685respectively. Table 4 showed that tocopherols (IDs 1, 2, 3,
and 4) are commonly docked in DPP-IV and PPAR-g with
conserved binding interactions (Fig. 6). Based on this con-
servation of interactions with important residues in the
active site of PPAR-g, the modulating role of the above-
mentioned botanicals can be proposed (Table 4). Different
conformers of botanicals determined by counting the
rotatable bonds, present in individual ligand were docked
in the active sites of three proteins (Table 5).
DPP-IV contains two sub-pockets S1 and S2. The hydro-
phobic S1 pocket is composed of residues V656, Y631, Y662,
W659, Y666, and V711, while the hydrophobic S2 pocket is
determined by the side chains of residues of R125, F357,
Y547, P550, Y631, and Y666. The five botanicals (IDs 1, 2, 3,
4 and 7) docked to DPP-IV, bound to DPP-IV in the S1 sub-
pocket with H-bonding (Glu205 and/or Y662 and/or Y666)
as well as residues in the S1 sub-pocket (Table 4; Fig. 6).
Moreover, botanicals with IDs1, 2, and 3 had hydrophobic
interactions with S630, Y547, and W629 residues. Similarly,
six botanicals (IDs 1, 2, 3, 4, 8, and 9) docked to PPAR-g
formed hydrogen bonds with H449 and hydrophobic in-
teractions with C285 (Table 4).
Most of the H-bonds and hydrophobic interactions were
found during tocopherol-target protein interactions. How-
ever, with DPP-IV, a- and b-tocopherols interacted through
additional H-bonds compared to g- and d-tocopherols.
Similarly, with PPAR-g, d-tocopherol interacted with one
additional hydrogen bond when compared to the other
three tocopherols. Some residues contributing to hydro-
phobic interactions also differed during the interaction of
tocopherols with DPP-IV and PPAR-g. The a-, b-, d-, and g-
tocopherols had similar/identical numbers of H-bondacceptors and donors, however, they differed marginally
with each other in terms of XlogP values (Fig. 7). Although,
a-tocopherol versus b-, d-, and g-tocopherols shared a high
similarity in 2D, they differed with each other (averaged
over 25 conformers of each tocopherol) in their 3D shape
similarity, which was calculated by the OEChem shape
toolkit42 (Table S6). The a-, b-, d-, and g-tocopherols had
differential docking behaviors (with respect to scores of
poses), despite being similar/identical with respect to H-
bond donors and acceptors, probably due to the difference
in 3D shape similarity among these tocopherols.
b. Docking without constraints
In nonconstraint docking, all of the tocopherols showed
interaction in the active sites of the proteins. Out of 10
compounds, eight, eight and nine botanicals showed in-
teractions with DPP-IV, PPAR-g, and PTP1 B, respectively
(Tables S3eS5; Fig. S1eS3).Discussion
DM is a chronic metabolic disorder, characterized by
glucose overproduction and glucose underutilization.
Although medical nutrition therapy and exercise are
important components of a diabetes management plan,
most patients need medication to normalize glucose levels.
Therapeutic options include sulfonylureas and other insulin
secretagogues, biguanides, a-glucosidase inhibitors, thia-
zolidinediones, and insulin.1 Extensive research has been
carried out worldwide on molecular targets for T2DM,
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Table 5 Number of conformers generated with respect to
number of rotatable bonds.
No. of rotatable bonds No. of max. conformers
0e2 200
3e5 300
6e8 500
9e11 1000
12e14 1500
15e17 2000
686 S.K. Bharti et al.including PPAR-g, PTP-1B, DPP-IV, etc. These therapeutic
targets are quite suitable for in silico analysis and rational
drug design in the development of newer antidiabetic
agents. Therefore, many molecular modeling and infor-
matics studies, such as molecular docking, pharmacophore
mapping, virtual screening, and pharmacoinformatics
studies have been performed on the drugs/leads/targets
associated with T2DM.5
PX-407 is a nonionic copolymer, commonly used as a
surfactant, emulsifying agent, and solubilizing agent in
pharmaceutical formulations. In rats, intraperitoneal
administration of PX-407 increases body weight, and man-
ifests hyperglycemia with a low degree of toxicity
(LD50  1.8 g/kg body weight). It causes impaired response
in the glucose tolerance test and a loss of b-cell sensitivity
to glucose. It is considered as a useful experimental model
to study the pathophysiological aspects, as well as thera-
peutic influences, of antihyperglycemic agents.26,54
The effects of medicinal plants/extracts in diabetic or-
ganisms are of great interest, due to their beneficial effects
on the metabolic profile. In the present study, the higher
dose of CPSE (DT5 group) presented a significant glucose-
lowering effect in diabetic rats, accompanied by a reduc-
tion of insulinemia and a decrease in insulin resistance,
evaluated by HOMA-IR. Therefore, we hypothesize that CPSE
administration at a higher dose was capable of improving
peripheral insulin resistance, albeit having an insignificant
effect on hepatic resistance, and propose that hyper-
insulinemia might be the spontaneous effect of insulin
resistance in the liver. These favorable effects of CPSE may
be attributed to the action of their antioxidant botanicals,
particularly tocopherols, which may therefore regulate the
hyperglycemia, lipogenesis, and hypertriglyceridemia asso-
ciated with T2DM.21,22 The pumpkin polysaccharides have
also been found to increase the SOD and glutathione
peroxidase activity and reduce the malonaldehyde in mouse
serum, which shows an increase in antioxidant capacity.55
Despite the amelioration in glucose metabolism, CPSE
treatment was unable to induce beneficial modifications in
the lipid profile (TGs and TC). This was supported by our
docking results, in which the CPSE botanicals showed poor
interactions with the PPAR-g ligand. However, it has
been proven that the product resulting from the meta-
bolism of g-tocopherol plays an important role in the pre-
vention of cardiac diseases and in the regulation of blood
pressure, probably by controlling the drainage of water
and of different metabolites in the body. The presence of
unsaturated fatty acids, such as oleic acid and linoleic
Figure 7 Comparison of physicochemical properties of 10 CPSE botanicals and native ligands bound to crystal structures of
dipeptidyl peptidase IV (DPP-IV), peroxisome proliferator-activated receptor gamma (PPAR-g), and protein-tyrosine phosphatase
1B (PTP-1B) calculated by the MolProp tool. Four parameters, namely molecular weights (MW), number of hydrogen bond acceptors
(HBA), number of hydrogen bond donors (HBD), and XlogP were used to evaluate the botanicals with the likelihood of orally active
drugs in humans according to ’The rule of 50 of Lipinski.69 However, natural products remain bioavailable and are often cited as an
exception to Lipinski’s rules.70,71 The number of rotatable bonds (RB) and polar surface area (PSA)72 of these compounds were also
calculated (see also Table S6).
In vivo and in silico validation of Cucurbita pepo tocopherol 687acid in pumpkin seeds reduces cholesterol levels in
rats.13,16,17,21,24e26
Hyperglycemia and hypertriglyceridemia are known to
increase the generation of reactive oxygen species (ROS)
and subsequent lipid peroxidation, which are known to
accelerate the pathogenesis of T2DM, as evidenced by the
glucose and lipid toxicity theories.1 The catalytic actions of
antioxidant enzymes are important for the effective
removal of oxygen radicals. It has been reported that to-
copherols are antioxidant molecules which prevent the
damage caused by free radicals on tissues via a mechanism
of membrane transfer.13,56 This is achieved by donating a
hydrogen atom to a peroxide radical, which results from thedegradation of unsaturated lipids and as a consequence,
tocopherols are minor but omnipresent components in
membranes.57 An increased generation of free radicals by
PX-407 induction to rats reduces the activities of antioxi-
dant enzymes, such as catalase, GST, and SOD, as observed
in the DC group rats.
Our study showed that CPSE treatment significantly
increased GLP-1 content in the cecum of diabetic rats,
accompanied by cecal tissue enlargement. This result was
also supported by our docking results, in which some of the
botanicals strongly inhibited DPP-IV. It has been docu-
mented that GLP1 has a number of important biological
effects that include, among others, release of insulin,
Table 6 2D and 3D similarity between native ligands and CPSE phytochemicals. 2D similarity is calculated from ECFP4 while 3D
similarity was calculated by TanimotoCombo.
Pub chem ID 222284 173183 92094 92729 14985 6857447 638072 5280489 448437 442634
N7 F
3D similarity 0.765 0.760 0.678 0.671 0.668 0.618 0.589 0.441 0.433 0.395
2D similarity 0.1047 0.1064 0.1064 0.1053 0.1042 0.1053 0.0211 0.0826 0.0721 0.0606
DRY
3D similarity 0.556 0.573 0.710 0.706 0.704 0.709 0.607 0.348 0.371 0.299
2D similarity 0.0714 0.0518 0.1658 0.1538 0.1421 0.1538 0.0923 0.0628 0.0617 0.0438
UN7
3D similarity 0.571 0.561 0.713 0.709 0.702 0.705 0.626 0.359 0.389 0.417
2D similarity 0.1053 0.1071 0.1667 0.1529 0.1163 0.1412 0.0824 0.101 0.1188 0.0893
688 S.K. Bharti et al.inhibition of glucagon and somatostatin, and maintenance
of b-cell mass.58 We also found that the insulin-positive cell
mass was increased after CPSE treatment, which could
explain the significant increase in fasting plasma insulin
levels, although this increase was not sufficient to
normalize fasting glycemia. Probably, these effects are
proportional to the duration of the treatment and are
potentially beneficial in the context of long-term
treatment.
PX-407 partially damages the pancreatic islets and so
decreases the number of b-cells and insulin globules.54 This
damage leads to an inflammation in the pancreas which is
known as insulitis. Our results showed that, in CPSE-treated
diabetic rats, there was a significant (p < 0.001) improve-
ment in the number of islets, as well as the grade of insu-
litis, in agreement with other studies.59,60 Antioxidant
compounds also increase the number of b-pancreatic cells
by enhancing the repair and restoration of these cells. It
has been well documented that administration of antioxi-
dants to diabetic rats significantly increases the number of
b-cells.61 Studies have indicated that administration of
quercetin to b-cells in vitro causes an increase in the
number of these cells, which is due to an increase in DNA
replication in pancreatic islet cells.61 It has been found
that saponin extracted from Cucurbitaceae plant colo-
cynth62 (Citrullus colocynthis) and flavonoid compounds,
including quercetin, with antioxidant activity possess anti-
hyperglycemic effects in diabetic rats.63 The increased b-
cell mass would increase the secretion of insulin, which
may increase the peripheral utilization of glucose.64 Hence,
one of the reasons behind the observed antihyperglycemic
activity of CPSE may be the repair and restoration of
pancreatic tissue to near normal values.
Pumpkin contains various biologically active compo-
nents, such as polysaccharides, para-aminobenzoic acid,
fixed oils, sterols, proteins, peptides, carotenoids, g-ami-
nobutyric acid, and vitamins.65e67 These botanicals exert
antidiabetic effects, probably synergistically. With the
possibility that botanicals may interact with the constitu-
ents to potentiate their antidiabetic effects, further
investigation regarding their interactions would be
rewarding.68
Further, in order to understand the mechanism of ac-
tion, constrained and nonconstrained docking studies were
performed by HYBRID and FRED programs for 10 CPSEbotanicals with respect to three antidiabetic proteins,
namely PPAR-g, PTP1 B, and DPP-IV. The 3D conformers of
these botanicals were used for docking with three proteins.
In the case of PPAR-g, it has been reported that the direct
interaction between a ligand and the C-terminal helix in
the ligand-binding domain (LBD), constituting the activa-
tion function-2 (AF-2), has a crucial function in the ligand-
induced receptor activation.6 Full agonists of PPAR-g form
hydrogen bonds with H499 on the AF-2 helix H12,46 whereas
partial agonists did not always interact with this helix to
activate PPAR-g.47 For DPP-IV inhibition, H-bonding with
Glu205, as well as extension of the hydrophobic part in the
S1 sub-pocket has been reported to be important. We
observed that a-tocopherol approximately formed a U-
shape while binding to PPAR-g, observed as critical for
agnostic activity.46 Moreover, in the case of DPP-IV, a-
tocopherol matched the shape of bound ligands present in
the crystal structure.Conclusion
The in vivo experiment against PX-407-induced diabetic
rats, fully supported by molecular docking, proves that C.
pepo seed extract is antioxidant and thus antidiabetic in
nature. Consequently, this study submits that C. pepo seed
extract is a supplement to the existing oral antidiabetic
drugs and it minimizes the transformation of pre-diabetics
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